Latigo Biotherapeutics, Inc. (LTGO)
NASDAQ: LTGO · Real-Time Price · USD
20.39
-0.43 (-2.07%)
Sep 23, 2026, 10:35 AM EDT - Market open
Latigo Biotherapeutics Market Cap
Latigo Biotherapeutics has a market cap or net worth of $1.35 billion as of September 23, 2026.
Market Cap
1.35B
Enterprise Value
1.33B
1-Year Change
n/a
Ranking
Category
Stock Price
$20.39
ChartMarket Cap Chart
Since the IPO on August 7, 2026, Latigo Biotherapeutics's market cap has increased from $1.08B to $1.35B, an increase of 24.85%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 23, 2026 | 1.35B | -3.41% |
| Sep 21, 2026 | 1.40B | -6.39% |
| Sep 18, 2026 | 1.50B | -5.77% |
| Sep 17, 2026 | 1.59B | 3.77% |
| Sep 16, 2026 | 1.53B | 0.22% |
| Sep 15, 2026 | 1.53B | 1.63% |
| Sep 14, 2026 | 1.50B | 2.21% |
| Sep 11, 2026 | 1.47B | 2.83% |
| Sep 10, 2026 | 1.43B | -5.53% |
| Sep 9, 2026 | 1.51B | -3.92% |
| Sep 8, 2026 | 1.57B | 2.99% |
| Sep 4, 2026 | 1.53B | 2.49% |
| Sep 3, 2026 | 1.49B | 8.26% |
| Sep 2, 2026 | 1.38B | -2.20% |
| Sep 1, 2026 | 1.41B | 1.09% |
| Aug 31, 2026 | 1.39B | -9.12% |
| Aug 28, 2026 | 1.53B | -3.08% |
| Aug 27, 2026 | 1.58B | 3.61% |
| Aug 26, 2026 | 1.53B | 6.91% |
| Aug 25, 2026 | 1.43B | 2.59% |
| Aug 24, 2026 | 1.39B | -1.65% |
| Aug 21, 2026 | 1.41B | 4.53% |
| Aug 20, 2026 | 1.35B | 2.20% |
| Aug 19, 2026 | 1.32B | 4.70% |
| Aug 18, 2026 | 1.26B | 3.63% |
| Aug 17, 2026 | 1.22B | -0.97% |
| Aug 14, 2026 | 1.23B | -2.84% |
| Aug 13, 2026 | 1.27B | 3.54% |
| Aug 12, 2026 | 1.23B | 4.62% |
| Aug 11, 2026 | 1.17B | -0.22% |
| Aug 10, 2026 | 1.17B | 8.40% |
| Aug 7, 2026 | 1.08B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| ArriVent BioPharma | 1.50B |
| Ascentage Pharma Group International | 1.47B |
| First Tracks Biotherapeutics | 1.47B |
| Avalyn Pharma | 1.44B |
| ORIC Pharmaceuticals | 1.40B |
| Alpha Tau Medical | 1.40B |
| Cullinan Therapeutics | 1.39B |
| Damora Therapeutics | 1.38B |